Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Edith Jones

Nurse Practitioner, Psychiatric/Mental Health Homer, AK Nurse Practitioner

NPI 1356993448 CMS profile 10549365

4300 Bartlett St, Homer, AK 99603

Open in the dashboard

General payments

$2,934

105 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edith Jones of Homer, AK is reported in the CMS Open Payments database as having received $2,934 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $710 11
2024 General $427 17
2023 General $1,158 47
2022 General $359 16
2021 General $280 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edith Jones
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Edith Jones were reported at $710. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Edith Jones Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $280 $166 $54–$482 $132
2022 $359 $195 $66–$559 $149
2023 $1,158 $233 $82–$673 $160
2024 $427 $236 $84–$688 $164
2025 $710 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $816 15 payments
  2. AbbVie, Inc. $499 25 payments
  3. Alkermes, Inc. $341 12 payments
  4. E.R. Squibb & Sons, L.L.C. $285 6 payments
  5. Otsuka America Pharmaceutical, Inc. $192 14 payments
  6. Axsome Therapeutics, Inc. $168 3 payments
  7. ITI, Inc. $156 7 payments
  8. Neurocrine Biosciences, Inc. $152 7 payments
  9. Janssen Scientific Affairs, LLC $96 1 payment
  10. Sunovion Pharmaceuticals Inc. $83 7 payments
  11. Other $145 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,887 104 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. INVEGA SUSTENNA $613 11 payments
  2. VRAYLAR $360 22 payments
  3. LYBALVI $318 11 payments
  4. SPRAVATO $264 4 payments
  5. ABILIFY MAINTENA $182 14 payments
  6. COBENFY $177 4 payments
  7. Auvelity $168 3 payments
  8. ARISTADA Cns $161 8 payments
  9. ARISTADA Cns $161 8 payments
  10. ARISTADA Cns $161 8 payments
  11. Other $1,772 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,494

Median for Nurse Practitioner: 389

Drug cost

$52,869

Median for Nurse Practitioner: $21,885

Branded share of claims

19.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 13 $17,945
Vyvanse Lisdexamfetamine Dimesylate Brand 18 $6,775
Methylphenidate Er (La) Methylphenidate Hcl Brand 13 $3,735
Lisdexamfetamine Dimesylate Generic 12 $3,303
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 30 $1,919
Atomoxetine Hcl Generic 25 $1,397
Lurasidone Hcl Generic 19 $1,393
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 41 $1,006
Buspirone Hcl Generic 68 $914
Aripiprazole Generic 51 $910

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COBENFY
  • E.R. Squibb & Sons, L.L.C. $108
$108 — —
VRAYLAR
  • AbbVie, Inc. $57
$57 13 —
Auvelity
  • Axsome Therapeutics, Inc. $43
$43 — —
ARISTADA
  • Alkermes, Inc. $42
$42 — —
LYBALVI
  • Alkermes, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record